Figures – Biotechnologies & Health in Japan
Japan Gross Domestic Product 2016 was about $4.9 trillions (7.97 % of the world economy).
–Japan has been ranked 16th by the Global Innovation Index 2016:
• 9th for the proportion of researchers in general population: 5.4 for 1.000 inhabitants
• 15th for academia/industry cooperation
• 3rd for its R&D intensity : 3.59% of its GDP as of june 2016
• 9th for clusters development
•1st on innovation quality –
–The 5th Science & Technology Basic Plan (2016-2020) plan on a combined private/public investment of 4% GDP in R&D, 1% coming from the government (about ¥26 trillions).
–According to the JBA, there were 591 bio-venture companies in 2014, about 150 of them being small firms (under 50 employees) according to the OECD.
–Medical devices and pharmaceuticals market: Japan is the second market worldwide with 10% of the market share.
–The biotechnology industry was valued at ¥3 trillion in 2015.
–Expected bioindustry social contribution in 2030 : market size ¥40 trillions, GDP ¥20 trillions, 80 millions jobs.
–Japanese regenerative medicine market prevision for 2030 : ¥1 trillion.
–The Japanese population was about 127 million in 2015 and is expected to fall to less than 85 million by 2050.
–People over 65 years old are approaching 30% of the population and are expected to exceed 40% by 2050.
100 ¥ = 0,89 $